Dutch regulatory expresses concern that narrow-spectrum penicillin is no longer available

28 September 2015

The Medicines Evaluation Board (MEB) of the Netherlands deems it extremely concerning that the antibiotics sodium penicillin G 1,000,000 IU, sodium penicillin G 10,000,000 IU and penidural will no longer be available.

These injections play an important role in the various treatment protocols followed by doctors. They are used in the treatment of diseases including pneumonia, syphilis and various infections of the skin, muscles and tendons. There are no comparable products on the market in the Netherlands. As these penicillins are no longer available, doctors will start using broad-spectrum antibiotics. This contradicts the aim of counter-acting resistance against antibiotics.

Resistance can be countered through the use - wherever possible - of targeted treatment using narrow-spectrum antibiotics. These narrow-spectrum antibiotics are only effective against a limited range of bacteria. The broad-spectrum antibiotics are effective against a much wider range of bacteria.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical